Corticosteroids
(8 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) | |||
Zeile 1: | Zeile 1: | ||
+ | {{up|PHA Biologicals}} | ||
{{tp|p=32149773|t=ä. Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial |pdf=|usr=}} | {{tp|p=32149773|t=ä. Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial |pdf=|usr=}} | ||
Zeile 5: | Zeile 6: | ||
{{tp|p=32321620|t=ä. Corticosteroid use for 2019-nCoV infection: A double-edged sword |pdf=|usr=}} | {{tp|p=32321620|t=ä. Corticosteroid use for 2019-nCoV infection: A double-edged sword |pdf=|usr=}} | ||
{{tp|p=32283153|t=ä. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-1 |pdf=|usr=}} | {{tp|p=32283153|t=ä. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-1 |pdf=|usr=}} | ||
+ | {{tp|p=32389783|t=2020. Re: Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19.|pdf=|usr=008}} | ||
{{tp|p=32122468|t=2020. On the use of corticosteroids for 2019-nCoV pneumonia |pdf=|usr=}} | {{tp|p=32122468|t=2020. On the use of corticosteroids for 2019-nCoV pneumonia |pdf=|usr=}} | ||
{{tp|p=32043983|t=2020. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury |pdf=|usr=}} | {{tp|p=32043983|t=2020. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury |pdf=|usr=}} | ||
Zeile 10: | Zeile 12: | ||
{{tp|p=32341331|t=2020. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia |pdf=|usr=}} | {{tp|p=32341331|t=2020. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia |pdf=|usr=}} | ||
{{tp|p=32133159|t=2020. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia |pdf=|usr=}} | {{tp|p=32133159|t=2020. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia |pdf=|usr=}} | ||
+ | {{tp|p=32266987|t=2020. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19) |pdf=|usr=}} | ||
+ | {{tp|p=32164084|t=2020. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia |pdf=|usr=}} | ||
+ | {{tp|p=32296012|t=2020. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia |pdf=|usr=}} | ||
+ | {{tp|p=C7189003|t=2020. Glukokortikoide und Covid-19 |pdf=|usr=}} | ||
+ | {{tp|p=32475851|t=2020. COVID-19: Stay Cool toward Corticosteroids.|pdf=|usr=007}} | ||
+ | {{tp|p=32409522|t=2020. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis.|pdf=|usr=007}} | ||
+ | {{tp|p=32427279|t=2020. Early Short Course Corticosteroids in Hospitalized Patients with COVID-19.|pdf=|usr=007}} | ||
+ | {{tp|p=32474331|t=2020. Corticosteroids and the hyper-inflammatory phase of the COVID-19 disease.|pdf=|usr=008}} | ||
+ | {{tp|p=32514902|t=2020. Systemic steroids in patients with COVID-19: pros and contras, an endocrinological point of view.|pdf=|usr=008}} | ||
+ | {{tp|p=32283144|t=2020. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis.|pdf=|usr=008}} | ||
+ | {{tp|p=32391369|t=2020. Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature.|pdf=|usr=008}} | ||
+ | {{tp|p=32417314|t=2020. Corticosteroid use in selected patients with severe acute respiratory distress syndrome related to COVID-19.|pdf=|usr=008}} | ||
+ | {{tp|p=32437628|t=2020. COVID-19, Asthma, and Inhaled Corticosteroids (ICS): Another Beneficial Effect of ICS?|pdf=|usr=007}} | ||
+ | {{tp|p=32470160|t=2020. Glucocorticoid therapy delays the clearance of SARS-CoV-2 RNA in an asymptomatic COVID-19 patient.|pdf=|usr=007}} | ||
+ | {{tp|p=32441786|t=2020. Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old.|pdf=|usr=007}} | ||
+ | {{tp|p=32034899|t=2020. [Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia].|pdf=|usr=007}} | ||
+ | {{tp|p=32479759|t=2020. Successful use of methylprednisolone for treating severe COVID-19.|pdf=|usr=008}} | ||
+ | {{tp|p=32496422|t=2020. Effects of Corticosteroid Treatment for Non-Severe COVID-19 Pneumonia: A Propensity Score-Based Analysis.|pdf=|usr=007}} | ||
+ | {{tp|p=32464115|t=2020. Caution against corticosteroid-based COVID-19 treatment.|pdf=|usr=009}} | ||
+ | {{tp|p=32519174|t=2020. What can we learn about corticosteroid therapy as a treatment for COVID-19?|pdf=|usr=009}} | ||
+ | {{tp|p=32532461|t=2020. Eficacia de los pulsos de corticoides en pacientes con sindrome de liberacion de citocinas inducido por infeccion por SARS-CoV-2.|pdf=|usr=009}} | ||
+ | {{tp|p=32514354|t=2020. High-dose, short-term corticosteroids for ARDS caused by COVID-19: a case series.|pdf=|usr=009}} | ||
+ | {{tp|p=32491104|t=2020. Clinical characteristics and therapeutic procedure for a critical case of novel coronavirus pneumonia treated with glucocorticoids and non-invasive ventilator treatment.|pdf=|usr=009}} | ||
+ | {{tp|p=32571831|t=2020. IMPACT OF GLUCOCORTICOID TREATMENT IN SARS-COV-2 INFECTION MORTALITY: A RETROSPECTIVE CONTROLLED COHORT STUDY.|pdf=|usr=010}} | ||
+ | {{tp|p=32548723|t=2020. Impact of anti-rheumatic drugs and steroids on clinical course and prognosis of COVID-19.|pdf=|usr=010}} | ||
+ | {{tp|p=32585180|t=2020. Use of inhaled corticosteroids in asthma and COVID-19 : Keep calm and carry on.|pdf=|usr=010}} | ||
+ | {{tp|p=32588377|t=2020. Corticosteroids in diabetes patients infected with COVID-19.|pdf=|usr=010}} | ||
+ | {{tp|p=32570995|t=2020. Short-Term Dexamethasone in Sars-CoV-2 Patients.|pdf=|usr=010}} | ||
+ | {{tp|p=32576548|t=2020. Covid-19: Demand for dexamethasone surges as RECOVERY trial publishes preprint.|pdf=|usr=010}} | ||
+ | {{tp|p=32546467|t=2020. Covid-19: Low dose steroid cuts death in ventilated patients by one third, trial finds.|pdf=|usr=010}} | ||
+ | {{tp|p=32590699|t=2020. ACTH 1-24 and other melanocortins for COVID-19 treatment.|pdf=|usr=010}} | ||
+ | {{tp|p=32566564|t=2020. Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis.|pdf=|usr=011}} | ||
+ | {{tp|p=32548616|t=2020. Corticosteroids in patients with COVID-19: what about the control group?|pdf=|usr=010}} | ||
+ | {{tp|p=32451729|t=2020. Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review.|pdf=|usr=011}} | ||
+ | {{tp|p=32588877|t=2020. High-dose but not low-dose corticosteroids potentially delay viral shedding of patients with COVID-19.|pdf=|usr=011}} | ||
+ | {{tp|p=32585016|t=2020. THE RIGHT TIME FOR STEROIDS IN COVID-19.|pdf=|usr=011}} | ||
+ | {{tp|p=32603802|t=2020. Corticosteroid administration for viral pneumonia: COVID-19 and beyond.|pdf=|usr=011}} | ||
+ | {{tp|p=32430057|t=2020. Adjuvant corticosteroid therapy for critically ill patients with COVID-19.|pdf=|usr=011}} | ||
+ | {{tp|p=32610262|t=2020. Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective.|pdf=|usr=011}} | ||
+ | {{tp|p=32394335|t=2020. Corticosteroids for critically ill COVID-19 patients with cytokine release syndrome: a limited case series.|pdf=|usr=011}} | ||
+ | {{tp|p=32551464|t=2020. Dexamethasone for COVID-19? Not so fast.|pdf=|usr=011}} | ||
+ | {{tp|p=32603493|t=2020. Methylprednisolone added to tocilizumab reduces mortality in SARS-CoV-2 pneumonia: An observational study.|pdf=|usr=011}} | ||
+ | {{tp|p=32482571|t=2020. Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic.|pdf=|usr=011}} | ||
+ | {{ttp|p=32546811|t=2020. Coronavirus breakthrough: dexamethasone is first drug shown to save lives.|pdf=|usr=011}} | ||
+ | {{tp|p=32538585|t=2020. Reply to: What we are talking about when we talk of steroid in COVID-19?|pdf=|usr=011}} | ||
+ | {{tp|p=32530507|t=2020. Can steroids reverse the severe COVID-19 induced "cytokine storm"?|pdf=|usr=011}} | ||
+ | {{tp|p=32383835|t=2020. Acute respiratory distress syndrome and steroids in the shadow of coronavirus disease 2019.|pdf=|usr=011}} | ||
+ | {{tp|p=32426753|t=2020. Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019.|pdf=|usr=015}} | ||
+ | {{tp|p=32536610|t=2020. Contrasting evidence for corticosteroid treatment for coronavirus-induced cytokine storm.|pdf=|usr=018}} | ||
+ | {{tp|p=32616373|t=2020. The influence of corticosteroid on patients with COVID-19 infection: A meta-analysis.|pdf=|usr=017}} | ||
+ | {{tp|p=32616381|t=2020. A critical evaluation of glucocorticoids in the management of severe COVID-19.|pdf=|usr=015}} | ||
+ | {{tp|p=32634602|t=2020. Corticosteroid therapy for patients with CoVID-19 pneumonia: a before-after study.|pdf=|usr=012}} | ||
+ | {{tp|p=32656044|t=2020. Pulse Therapy With Corticosteroids and Intravenous Immunoglobulin in the Management of Severe Tocilizumab-Resistant COVID-19: A Report of Three Clinical Cases.|pdf=|usr=014}} | ||
+ | {{tp|p=32659271|t=2020. Pros and cons of corticosteroid therapy for COVID-19 patients.|pdf=|usr=014}} | ||
+ | {{tp|p=32668178|t=2020. Inhaled Corticosteroids and COVID-19.|pdf=|usr=014}} | ||
+ | {{tp|p=32671349|t=2020. Evidence of Steroids in Patients With Acute Respiratory Distress Syndrome in Coronavirus Disease 2019.|pdf=|usr=018}} | ||
+ | {{tp|p=32675436|t=2020. Tailoring steroids in the treatment of COVID-19 pneumonia assisted by CT scans: Three case reports.|pdf=|usr=014}} | ||
+ | {{tp|p=32696006|t=2020. Corticosteroid Administration Is Associated With Improved Outcome in Patients With Severe Acute Respiratory Syndrome Coronavirus 2-Related Acute Respiratory Distress Syndrome.|pdf=|usr=015}} | ||
+ | {{tp|p=32697000|t=2020. Corticosteroids-induced osteonecrosis in COVID-19: a call for caution.|pdf=|usr=014}} | ||
+ | {{tp|p=32719766|t=2020. Clinical Use of Short-Course and Low-Dose Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia Progression.|pdf=|usr=017}} | ||
+ | {{tp|p=32720612|t=2020. [Steroid pulse therapy (WAYFARER Study)].|pdf=|usr=014}} | ||
+ | {{tp|p=32668164|t=2020. Reply to: Inhaled Corticosteroids and COVID-19.|pdf=|usr=014}} | ||
+ | {{tp|p=32726951|t=2020. Efficacy of Corticosteroids in Patients with SARS, MERS and COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=017}} | ||
+ | {{tp|p=32730151|t=2020. Time-critical administration of corticosteroid rescue therapy for COVID-19 pneumonitis in a ward-based patient with chronic obstructive pulmonary disease.|pdf=|usr=018}} | ||
+ | {{tp|p=32734777|t=2020. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis.|pdf=|usr=017}} | ||
+ | {{tp|p=32738928|t=2020. Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?|pdf=|usr=017}} | ||
+ | {{tp|p=32744591|t=2020. The Uncertain Role of Corticosteroids in the Treatment of COVID-19.|pdf=|usr=017}} | ||
+ | {{tp|p=32744600|t=2020. The Uncertain Role of Corticosteroids in the Treatment of COVID-19-Reply.|pdf=|usr=017}} | ||
+ | {{tp|p=32744622|t=2020. The Uncertain Role of Corticosteroids in the Treatment of COVID-19.|pdf=|usr=017}} | ||
+ | {{tp|p=32756215|t=2020. Therapeutic response to corticosteroids in a critically ill patient with COVID-19: A case report.|pdf=|usr=017}} | ||
+ | {{tp|p=32761166|t=2020. COVID-19 and Dexamethasone: A Potential Strategy to Avoid Steroid-Related Strongyloides Hyperinfection.|pdf=|usr=017}} | ||
+ | {{tp|p=32760915|t=2020. Glucocorticoids save lives in COVID-19 patients.|pdf=|usr=017}} | ||
+ | {{tp|p=32763262|t=2020. The proper use of corticosteroids for 2019-nCov pneumonia: Towards promising results?|pdf=|usr=017}} | ||
+ | {{tp|p=32767349|t=2020. Corticosteroid therapy for patients with severe novel Coronavirus disease 2019.|pdf=|usr=017}} | ||
+ | {{tp|p=32769659|t=2020. Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19).|pdf=|usr=017}} | ||
+ | {{tp|p=32778507|t=2020. COVID-19 and steroid therapy: Impact on diabetes.|pdf=|usr=017}} | ||
+ | {{tp|p=32778829|t=2020. After 62 years of regulating immunity, dexamethasone meets COVID-19.|pdf=|usr=017}} | ||
+ | {{tp|p=32792492|t=2020. Clinical characteristics and corticosteroids application of different clinical types in patients with corona virus disease 2019.|pdf=|usr=018}} | ||
+ | {{tp|p=32795143|t=2020. Corticosteroid prevents COVID-19 progression within its therapeutic window: a multicentre, proof-of-concept, observational study.|pdf=|usr=018}} | ||
+ | {{tp|p=32796809|t=2020. Short-Term Corticosteroid Therapy for Early Exacerbation of COVID-19 Pneumonia: A Case Report.|pdf=|usr=018}} | ||
+ | {{tp|p=32802540|t=2020. Oral Corticosteroid Relieves Post-COVID-19 Anosmia in a 35-Year-Old Patient.|pdf=|usr=018}} | ||
+ | {{ttp|p=32819962|t=2020. Steroids in COVID-19: An overview.|pdf=|usr=019}} | ||
+ | {{tp|p=32829047|t=2020. CORTICOSTEROIDS IN THE TREATMENT OF SEVERE COVID-19 LUNG DISEASE.|pdf=|usr=018}} | ||
+ | {{tp|p=32860209|t=2020. What we have to know about corticosteroids use during Sars-Cov-2 infection.|pdf=|usr=018}} | ||
+ | {{tp|p=32860964|t=2020. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19).|pdf=|usr=019}} | ||
+ | {{tp|p=32861345|t=2020. Migratory Pulmonary Infiltrates in a Patient With COVID-19 Infection and the Role of Corticosteroids.|pdf=|usr=018}} | ||
+ | {{tp|p=32868989|t=2020. Combination treatment of short-course systemic corticosteroid and favipiravir in a successfully treated case of critically ill COVID-19 pneumonia with COPD.|pdf=|usr=018}} | ||
+ | {{tp|p=32876693|t=2020. Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic.|pdf=|usr=019}} | ||
+ | {{tp|p=32876689|t=2020. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial.|pdf=|usr=019}} | ||
+ | {{tp|p=32876695|t=2020. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.|pdf=|usr=019}} | ||
+ | {{tp|p=32876694|t=2020. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.|pdf=|usr=019}} | ||
+ | {{tp|p=32876697|t=2020. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.|pdf=|usr=019}} | ||
+ | {{tp|p=32878286|t=2020. Duration of COVID-19: Data from an Italian Cohort and Potential Role for Steroids.|pdf=|usr=018}} | ||
+ | {{tp|p=32880102|t=2020. Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study.|pdf=|usr=018}} | ||
+ | {{tp|p=32880390|t=2020. Systemic corticosteroids and mortality in severe and critical COVID-19 patients in Wuhan, China.|pdf=|usr=018}} | ||
+ | {{tp|p=32881007|t=2020. Are the steroids a blanket solution for COVID-19? a systematic review and meta-analysis.|pdf=|usr=018}} | ||
+ | {{tp|p=32888976|t=2020. Early short-course corticosteroids and furosemide combination to treat non-critically ill COVID-19 patients: An observational cohort study.|pdf=|usr=018}} | ||
+ | {{tp|p=32900168|t=2020. Pasient med alvorlig covid-19 behandlet med steroider.|pdf=|usr=019}} | ||
+ | {{tp|p=32903258|t=2020. Efficacy of corticosteroids in non-intensive care unit patients with COVID-19 pneumonia from the New York Metropolitan region.|pdf=|usr=019}} | ||
+ | {{tp|p=32903363|t=2020. Corticosteroid Use in the Treatment of COVID-19: A Multicenter Retrospective Study in Hunan, China.|pdf=|usr=019}} | ||
+ | {{tp|p=32931775|t=2020. The association between corticosteroid uses and mortality among severe COVID-19 patients.|pdf=|usr=019}} | ||
+ | {{tp|p=32936438|t=2020. Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All.|pdf=|usr=019}} | ||
+ | {{tp|p=32941927|t=2020. Corticosteroid therapy is associated with the delay of SARS-CoV-2 clearance in COVID-19 patients.|pdf=|usr=019}} | ||
+ | {{tp|p=32948881|t=2020. Corticosteroid-related in-hospital hyperglycemia: does it negate mortality benefits in COVID-19?|pdf=|usr=019}} | ||
+ | {{tp|p=32953385|t=2020. Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All.|pdf=|usr=019}} | ||
+ | {{tp|p=32971254|t=2020. Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study.|pdf=|usr=019}} | ||
+ | {{tp|p=32976118|t=2020. Corticosteroids, COVID-19 pneumonia, and acute respiratory distress syndrome.|pdf=|usr=019}} | ||
+ | {{tp|p=32983928|t=2020. The Application of Corticosteroids in COVID-19: A Two-edged Sword.|pdf=|usr=019}} | ||
+ | {{tp|p=32986226|t=2020. Effect of Corticosteroid Therapy on the Duration of SARS-CoV-2 Clearance in Patients with Mild COVID-19: A Retrospective Cohort Study.|pdf=|usr=019}} | ||
+ | {{tp|p=32988730|t=2020. Corticosteroids as adjunctive therapy in the treatment of coronavirus disease 2019: A report of two cases and literature review.|pdf=|usr=019}} | ||
+ | {{tp|p=33005428|t=2020. Late i.v. steroid treatment for severe COVID-19-induced acute respiratory distress syndrome: a case report.|pdf=|usr=019}} | ||
+ | {{tp|p=33007478|t=2020. Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19.|pdf=|usr=019}} | ||
+ | {{tp|p=33008778|t=2020. Association of corticosteroids use and outcomes in COVID-19 patients: A systematic review and meta-analysis.|pdf=|usr=019}} | ||
+ | {{ttp|p=33013412|t=2020. Efficacy and Safety of Corticosteroid Treatment in Patients With COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=019}} | ||
+ | {{ttp|p=33026460|t=2020. The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19.|pdf=|usr=019}} | ||
+ | {{tp|p=33043249|t=2020. Reactivation of SARS-CoV-2 after Asymptomatic Infection while on High-Dose Corticosteroids. Case Report.|pdf=|usr=020}} | ||
+ | {{ttp|p=33055254|t=2020. The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells.|pdf=|usr=020}} | ||
+ | {{tp|p=33062586|t=2020. Corticosteroids: A Controversial Therapy for Coronavirus Disease 2019.|pdf=|usr=020}} | ||
+ | {{ttp|p=33068560|t=2020. Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon.|pdf=|usr=020}} | ||
+ | {{ttp|p=33083317|t=2020. Corticosteroids on the Management of Coronavirus Disease 2019 (COVID-19): A Systemic Review and Meta-Analysis.|pdf=|usr=020}} | ||
+ | {{tp|p=33083917|t=2020. High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study.|pdf=|usr=020}} | ||
+ | {{tp|p=33094701|t=2020. Potential therapeutic use of corticosteroids as SARS CoV-2 main protease inhibitors: a computational study.|pdf=|usr=020}} | ||
+ | {{tp|p=33100248|t=2020. Effectiveness of steroid treatment for SARS-CoV-2 pneumonia with COP-like reaction: a case report.|pdf=|usr=020}} | ||
+ | {{tp|p=33103063|t=2020. Corticosteroids in COVID-19: Is it Rational? A Systematic Review and Meta-Analysis.|pdf=|usr=020}} | ||
+ | {{tp|p=33107607|t=2020. Corticosteroids for COVID-19 patients requiring oxygen support? Yes, but not for everyone: Effect of corticosteroids on mortality and intensive care unit admission in patients with COVID-19 according to patients' oxygen requirements.|pdf=|usr=020}} | ||
+ | {{tp|p=33115658|t=2020. Lack of detrimental effect of corticosteroids on antibody responses to SARS-CoV-2 and viral clearance in patients hospitalized with COVID-19.|pdf=|usr=020}} | ||
+ | {{tp|p=33115684|t=2020. COVID-19, steroids and other immunomodulators: The jigsaw is not complete.|pdf=|usr=020}} | ||
+ | {{tp|p=33119227|t=2020. Use of corticosteroids in SARS-CoV-2 infection: foe, or can they become a friend?|pdf=|usr=020}} | ||
+ | {{tp|p=33121512|t=2020. Corticosteroids in severe COVID-19: a critical view of the evidence.|pdf=|usr=020}} | ||
+ | {{tp|p=33123934|t=2020. Delayed hospital admission and high-dose corticosteroids potentially prolong SARS-CoV-2 RNA detection duration of patients with COVID-19.|pdf=|usr=020}} | ||
+ | {{tp|p=33129791|t=2020. "Impact of Corticosteroids in COVID-19 Outcomes: Systematic Review and Meta-Analysis".|pdf=|usr=020}} | ||
+ | {{tp|p=33141117|t=2020. Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome.|pdf=|usr=020}} | ||
+ | {{tp|p=33156381|t=2020. Impact of late administration of corticosteroids in COVID-19 ARDS.|pdf=|usr=020}} | ||
+ | {{tp|p=33172477|t=2020. Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis.|pdf=|usr=020}} | ||
+ | {{tp|p=33173161|t=2020. Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia.|pdf=|usr=020}} | ||
+ | {{tp|p=33180190|t=2020. Steroid administration in the Covid-19 era; timing does matter!|pdf=|usr=020}} | ||
+ | {{ttp|p=33183091|t=2020. Time-course analysis reveals that corticosteroids resuscitate diminished CD8+ T cells in COVID-19: a retrospective cohort study.|pdf=|usr=021}} | ||
+ | {{tp|p=33183113|t=2020. Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: a benefit of inhaled corticosteroids?|pdf=|usr=021}} | ||
+ | {{tp|p=33194871|t=2020. Late Worsening of COVID-19 Pneumonia: Successful Treatment with Ruxolitinib and Steroid.|pdf=|usr=020}} | ||
+ | {{tp|p=33219091|t=2020. Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management.|pdf=|usr=021}} | ||
+ | {{ttp|p=33221521|t=2020. Corticosteroid therapy in COVID-19 patients: Don't forget venous thromboembolism.|pdf=|usr=022}} | ||
+ | {{tp|p=33229355|t=2020. Efficacite et innocuite des corticosteroides dans le traitement de la COVID-19 selon des donnees pour la COVID-19, d'autres infections aux coronavirus, l'influenza, la pneumonie extrahospitaliere et le syndrome de detresse respiratoire aigue : revue systematique et meta-analyse.|pdf=|usr=022}} | ||
+ | {{tp|p=33235253|t=2020. Low-dose corticosteroid combined with immunoglobulin reverses deterioration in severe cases with COVID-19.|pdf=|usr=021}} | ||
+ | {{tp|p=33235888|t=2020. Antivirals With Adjunctive Corticosteroids Prevent Clinical Progression of Early Coronavirus 2019 Pneumonia: A Retrospective Cohort Study.|pdf=|usr=021}} | ||
+ | {{tp|p=33245242|t=2020. Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-2019.|pdf=|usr=022}} | ||
+ | {{tp|p=33248469|t=2020. Corticosteroids for COVID-19: the search for an optimum duration of therapy.|pdf=|usr=021}} | ||
+ | {{tp|p=33249430|t=2020. Effect of steroids on Covid-19 mortality risk: a Bayesian interpretation.|pdf=|usr=021}} | ||
+ | {{tp|p=33249945|t=2020. Corticosteroids treatment in severe patients with COVID-19: a propensity score matching study.|pdf=|usr=021}} | ||
+ | {{tp|p=33254551|t=2020. Can roflumilast become steroid-sparing alternative in the treatment of COVID-19?|pdf=|usr=022}} | ||
+ | {{tp|p=33260010|t=2020. COVID-19 and non-COVID ARDS patients demonstrate a distinct response to low dose steroids- A retrospective observational study.|pdf=|usr=022}} | ||
+ | {{ttp|p=33262415|t=2020. A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19.|pdf=|usr=022}} | ||
+ | {{tp|p=33263084|t=2020. Association between high-dose steroid therapy, respiratory function, and time to discharge in patients with COVID-19: Cohort study.|pdf=|usr=022}} | ||
+ | {{tp|p=33264251|t=2020. Use of Corticosteroids in COVID-19: Should It Be Considered as a Standard-of-Care Therapy?|pdf=|usr=022}} | ||
+ | {{tp|p=33274479|t=2020. Cyclosporine A plus low-dose steroid treatment in COVID-19 improves clinical outcomes in patients with moderate to severe disease. A pilot study.|pdf=|usr=022}} | ||
+ | {{tp|p=33277573|t=2020. Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19.|pdf=|usr=022}} | ||
+ | {{tp|p=33280066|t=2020. Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study.|pdf=|usr=022}} | ||
+ | {{tp|p=33282314|t=2021. Improvement of COVID-19 with renal failure and paralytic ileus by using steroids.|pdf=|usr=022}} | ||
+ | {{tp|p=33290446|t=2020. Efficacy of corticosteroid therapy in the treatment of long- lasting olfactory disorders in COVID-19 patients.|pdf=|usr=022}} | ||
+ | {{tp|p=33298370|t=2020. Corticosteroids for Patients With Coronavirus Disease 2019 (COVID-19) With Different Disease Severity: A Meta-Analysis of Randomized Clinical Trials.|pdf=|usr=023}} | ||
+ | {{tp|p=33301928|t=2020. Corticosteroids in patients hospitalised for COVID-19 pneumonia who require oxygen: observational comparative study using routine care data.|pdf=|usr=023}} | ||
+ | {{tp|p=C7255263|t=2020. Use of corticosteroids in asthma and COPD patients with or without COVID-19.|pdf=|usr=015}} | ||
+ | {{tp|p=C7298510|t=?. Steroids: A Therapeutic Option for COVID-19 Pneumonia Patients With ESRD?|pdf=|usr=015}} | ||
+ | {{tp|p=C7303657|t=?. Systemic steroids and risk of fecal-oral shedding and increased transmission of SARS-Cov-2 in pemphigus cases???.|pdf=|usr=015}} | ||
+ | {{tp|p=C7346767|t=2020. The use of corticosteroids for COVID-19 infection.|pdf=|usr=015}} | ||
+ | {{tp|p=C7598544|t=2020. 153 Do Hydroxychloroquine Disease-Modifying Antirheumatic Agents or Steroids Serve to Prevent COVID-19 Infection?|pdf=|usr=023}} | ||
+ | {{tp|p=C7661810|t=2020. Tocilizumab/unspecified corticosteroids: Spinal epidural abscess: 2 case report.|pdf=|usr=023}} | ||
+ | {{tp|p=C7677437|t=2020. Enoxaparin sodium/methylprednisolone: Cytomegalovirus reactivation gastrointestinal haemorrhage and off-label use: case report.|pdf=|usr=023}} | ||
+ | {{tp|p=C7726300|t=2020. Methylprednisolone/tocilizumab: Disseminated strongyloidiasis and off-label use: case report.|pdf=|usr=023}} | ||
+ | {{tp|p=C7726305|t=2020. Gasorelin/prednisolone: COVID-19 infection and weight increase : case report.|pdf=|usr=023}} | ||
+ | {{tp|p=32696008|t=2020. The Combination of Tocilizumab and Methylprednisolone Along With Initial Lung Recruitment Strategy in Coronavirus Disease 2019 Patients Requiring Mechanical Ventilation: A Series of 21 Consecutive Cases.|pdf=|usr=015}} | ||
+ | {{tp|p=32772069|t=2020. Clinical Outcomes Associated with Methylprednisolone in Mechanically Ventilated Patients with COVID-19.|pdf=|usr=017}} | ||
+ | {{tp|p=32785710|t=2020. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial.|pdf=|usr=019}} | ||
+ | {{tp|p=32816700|t=2020. Response to: 'High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumab' by Conticini et al.|pdf=|usr=018}} | ||
+ | {{tp|p=32816701|t=2020. High dosage of methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to tocilizumab.|pdf=|usr=018}} | ||
+ | {{tp|p=32845289|t=2020. Methylprednisolone for COVID-19: Was Benjamin Rush prescient?|pdf=|usr=018}} | ||
+ | {{tp|p=32893160|t=2020. Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases.|pdf=|usr=019}} | ||
+ | {{tp|p=32943404|t=2020. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial.|pdf=|usr=019}} | ||
+ | {{tp|p=32954492|t=2020. The role of methylprednisolone on preventing disease progression for hospitalized patients with severe COVID-19.|pdf=|usr=019}} | ||
+ | {{tp|p=32960899|t=2020. Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data.|pdf=|usr=019}} | ||
+ | {{tp|p=32995261|t=2020. Methylprednisolone pulse therapy: An alternative management of severe COVID-19.|pdf=|usr=019}} | ||
+ | {{tp|p=33072814|t=2020. Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia.|pdf=|usr=020}} | ||
+ | {{tp|p=33109497|t=2020. Computational studies reveal mechanism by which quinone derivatives can inhibit SARS-CoV-2. Study of embelin and two therapeutic compounds of interest, methyl prednisolone and dexamethasone.|pdf=|usr=020}} | ||
+ | {{tp|p=33176176|t=2020. Early, low-dose, short-term methylprednisolone decreased the mortality in critical COVID-19 patients: A multicenter retrospective cohort study.|pdf=|usr=020}} | ||
+ | {{tp|p=33194485|t=2020. Comparison of Efficacy of Dexamethasone and Methylprednisolone in Improving PaO2/FiO2 Ratio Among COVID-19 Patients.|pdf=|usr=021}} | ||
+ | {{tp|p=33200031|t=2020. Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease.|pdf=|usr=021}} | ||
+ | {{tp|p=33219551|t=2020. High-dose methylprednisolone in nonintubated patients with severe COVID-19 pneumonia.|pdf=|usr=021}} | ||
+ | {{tp|p=33220354|t=2020. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study.|pdf=|usr=022}} | ||
+ | {{tp|p=33225306|t=2020. Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease 2019.|pdf=|usr=021}} | ||
+ | {{tp|p=33225870|t=2020. In silico screening predicts common cold drug Dextromethorphan along with Prednisolone and Dexamethasone can be effective against novel Coronavirus disease (COVID-19).|pdf=|usr=021}} | ||
+ | {{tp|p=33230502|t=2020. Successful recovery from coronavirus disease 2019 in a living kidney transplant recipient using low-dose methylprednisolone.|pdf=|usr=022}} | ||
+ | {{tp|p=33318924|t=2020. Successful treatment with methyl-prednisolone pulses for the late phase of COVID-19 with respiratory failure: A single-center case series.|pdf=|usr=023}} | ||
+ | {{tp|p=C7212250|t=2020. Prednisone: Coronavirus disease 2019: case report.|pdf=|usr=015}} | ||
+ | {{tp|p=C7303433|t=2020. Methylprednisolone: Decrease in T cell count following off label use: case report.|pdf=|usr=015}} | ||
+ | {{tp|p=C7317072|t=2020. Methylprednisolone/prednisone: Accelerated viral replication following an off-label treatment: case report.|pdf=|usr=015}} | ||
+ | {{tp|p=C7648232|t=2020. Prednisolone/tacrolimus: COVID-19 infection: case report.|pdf=|usr=023}} | ||
+ | {{tp|p=33229384|t=2020. Dexamethasone or hydrocortisone in COVID-19?|pdf=|usr=021}} | ||
+ | {{tp|p=33232277|t=2020. Estimating the release of inflammatory factors and use of glucocorticoid therapy for COVID-19 patients with comorbidities.|pdf=|usr=021}} | ||
+ | {{tp|p=33308854|t=?. Cuestiones por resolver en el tratamiento con glucocorticoides de la infección COVID-19.|pdf=|usr=023}} | ||
+ | {{tp|p=C7351423|t=?. Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection?.|pdf=|usr=015}} | ||
+ | {{tp|p=C7648207|t=2020. Adalimumab/anakinra/dexamethasone: COVID-19 infection cytomegalovirus reactivation and off-label use: case report.|pdf=|usr=023}} | ||
+ | {{tp|p=32620554|t=2020. Dexamethasone in the management of covid -19.|pdf=|usr=012}} | ||
+ | {{tp|p=32636478|t=2020. Dexamethasone to the rescue.|pdf=|usr=015}} | ||
+ | {{tp|p=32674177|t=2020. Therapie mit Dexamethason bei Patienten mit COVID-19.|pdf=|usr=014}} | ||
+ | {{tp|p=32678530|t=2020. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report.|pdf=|usr=014}} | ||
+ | {{tp|p=32684095|t=2020. Worrying situation regarding the use of dexamethasone for COVID-19.|pdf=|usr=018}} | ||
+ | {{tp|p=32690491|t=2020. Dexamethasone for COVID-19: preliminary findings.|pdf=|usr=014}} | ||
+ | {{tp|p=32706553|t=2020. Audio Interview: Dexamethasone and Covid-19.|pdf=|usr=014}} | ||
+ | {{tp|p=32740972|t=2020. Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes.|pdf=|usr=017}} | ||
+ | {{tp|p=32747742|t=2020. Dexamethasone nanomedicines for COVID-19.|pdf=|usr=017}} | ||
+ | {{tp|p=32791213|t=2020. Dexamethasone: A boon for critically ill COVID-19 patients?|pdf=|usr=018}} | ||
+ | {{tp|p=32874905|t=2020. Dexamethasone in severe COVID-19 infection: A case series.|pdf=|usr=018}} | ||
+ | {{tp|p=32887677|t=2020. Covid-19: Hydrocortisone can be used as alternative to dexamethasone, review finds.|pdf=|usr=018}} | ||
+ | {{tp|p=32896649|t=2020. Dexamethasone to combat cytokine storm in COVID-19: Clinical trials and preliminary evidence.|pdf=|usr=019}} | ||
+ | {{tp|p=32922210|t=2020. Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost?|pdf=|usr=019}} | ||
+ | {{tp|p=32922517|t=2020. Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes.|pdf=|usr=019}} | ||
+ | {{ttp|p=32924825|t=2020. Computational insight of dexamethasone against potential targets of SARS-CoV-2.|pdf=|usr=019}} | ||
+ | {{tp|p=33000510|t=2020. Molecular and functional resemblance of dexamethasone and quercetin: A paradigm worth exploring in dexamethasone-nonresponsive COVID-19 patients.|pdf=|usr=020}} | ||
+ | {{tp|p=33023445|t=2020. Epidemiological Situation and Efficacy of Dexamethasone for the treatment planning of COVID-19: A perspective review.|pdf=|usr=020}} | ||
+ | {{tp|p=33035967|t=2020. COVID-19, myocardial edema and dexamethasone.|pdf=|usr=020}} | ||
+ | {{tp|p=33053024|t=2020. Sindrome do desconforto respiratorio agudo associada a COVID-19 tratada com Dexametasona (CoDEX).|pdf=|usr=020}} | ||
+ | {{tp|p=33063792|t=2020. Molecular determinants of vascular transport of dexamethasone in COVID-19 therapy.|pdf=|usr=020}} | ||
+ | {{tp|p=33077267|t=2020. Chez les sujets hospitalises pour COVID-19, est-ce que la dexamethasone diminue la mortalite a 28jours comparativement au traitement standard ?|pdf=|usr=020}} | ||
+ | {{tp|p=33129421|t=2020. Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties.|pdf=|usr=020}} | ||
+ | {{tp|p=33137605|t=2020. Can dexamethasone prevent the seizures induced by SARS-CoV-2 infection?|pdf=|usr=020}} | ||
+ | {{tp|p=33163859|t=2020. Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review.|pdf=|usr=020}} | ||
+ | {{tp|p=33233748|t=2020. Biomimetic Nanoparticles Potentiate the Anti-Inflammatory Properties of Dexamethasone and Reduce the Cytokine Storm Syndrome: An Additional Weapon against COVID-19?|pdf=|usr=021}} | ||
+ | {{tp|p=33251412|t=2020. Chemocentric Informatics Analysis: Dexamethasone Versus Combination Therapy for COVID-19.|pdf=|usr=021}} | ||
+ | {{tp|p=33293892|t=2020. Dexamethason.|pdf=|usr=023}} | ||
+ | {{tp|p=C7343652|t=2020. The use of dexamethasone in the treatment of COVID-19.|pdf=|usr=015}} |
Aktuelle Version vom 11. April 2021, 21:18 Uhr
PHA Biologicals |
32149773 ä. Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial
32272008 2020. Early preemptive immunomodulators (corticosteroids) for severe pneumonia patients infected with SARS-CoV-2
32341100 2020. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective
32321620 ä. Corticosteroid use for 2019-nCoV infection: A double-edged sword
32283153 ä. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-1
32389783 2020. Re: Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19.
32122468 2020. On the use of corticosteroids for 2019-nCoV pneumonia
32043983 2020. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
32372026 ä. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis
32341331 2020. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia
32133159 2020. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia
32266987 2020. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19)
32164084 2020. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia
32296012 2020. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia
C7189003 2020. Glukokortikoide und Covid-19
32475851 2020. COVID-19: Stay Cool toward Corticosteroids.
32409522 2020. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis.
32427279 2020. Early Short Course Corticosteroids in Hospitalized Patients with COVID-19.
32474331 2020. Corticosteroids and the hyper-inflammatory phase of the COVID-19 disease.
32514902 2020. Systemic steroids in patients with COVID-19: pros and contras, an endocrinological point of view.
32283144 2020. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis.
32391369 2020. Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature.
32417314 2020. Corticosteroid use in selected patients with severe acute respiratory distress syndrome related to COVID-19.
32437628 2020. COVID-19, Asthma, and Inhaled Corticosteroids (ICS): Another Beneficial Effect of ICS?
32470160 2020. Glucocorticoid therapy delays the clearance of SARS-CoV-2 RNA in an asymptomatic COVID-19 patient.
32441786 2020. Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old.
32034899 2020. [Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia].
32479759 2020. Successful use of methylprednisolone for treating severe COVID-19.
32496422 2020. Effects of Corticosteroid Treatment for Non-Severe COVID-19 Pneumonia: A Propensity Score-Based Analysis.
32464115 2020. Caution against corticosteroid-based COVID-19 treatment.
32519174 2020. What can we learn about corticosteroid therapy as a treatment for COVID-19?
32532461 2020. Eficacia de los pulsos de corticoides en pacientes con sindrome de liberacion de citocinas inducido por infeccion por SARS-CoV-2.
32514354 2020. High-dose, short-term corticosteroids for ARDS caused by COVID-19: a case series.
32491104 2020. Clinical characteristics and therapeutic procedure for a critical case of novel coronavirus pneumonia treated with glucocorticoids and non-invasive ventilator treatment.
32571831 2020. IMPACT OF GLUCOCORTICOID TREATMENT IN SARS-COV-2 INFECTION MORTALITY: A RETROSPECTIVE CONTROLLED COHORT STUDY.
32548723 2020. Impact of anti-rheumatic drugs and steroids on clinical course and prognosis of COVID-19.
32585180 2020. Use of inhaled corticosteroids in asthma and COVID-19 : Keep calm and carry on.
32588377 2020. Corticosteroids in diabetes patients infected with COVID-19.
32570995 2020. Short-Term Dexamethasone in Sars-CoV-2 Patients.
32576548 2020. Covid-19: Demand for dexamethasone surges as RECOVERY trial publishes preprint.
32546467 2020. Covid-19: Low dose steroid cuts death in ventilated patients by one third, trial finds.
32590699 2020. ACTH 1-24 and other melanocortins for COVID-19 treatment.
32566564 2020. Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis.
32548616 2020. Corticosteroids in patients with COVID-19: what about the control group?
32451729 2020. Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review.
32588877 2020. High-dose but not low-dose corticosteroids potentially delay viral shedding of patients with COVID-19.
32585016 2020. THE RIGHT TIME FOR STEROIDS IN COVID-19.
32603802 2020. Corticosteroid administration for viral pneumonia: COVID-19 and beyond.
32430057 2020. Adjuvant corticosteroid therapy for critically ill patients with COVID-19.
32610262 2020. Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective.
32394335 2020. Corticosteroids for critically ill COVID-19 patients with cytokine release syndrome: a limited case series.
32551464 2020. Dexamethasone for COVID-19? Not so fast.
32603493 2020. Methylprednisolone added to tocilizumab reduces mortality in SARS-CoV-2 pneumonia: An observational study.
32482571 2020. Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic.
32546811 2020. Coronavirus breakthrough: dexamethasone is first drug shown to save lives. |
32538585 2020. Reply to: What we are talking about when we talk of steroid in COVID-19?
32530507 2020. Can steroids reverse the severe COVID-19 induced "cytokine storm"?
32383835 2020. Acute respiratory distress syndrome and steroids in the shadow of coronavirus disease 2019.
32426753 2020. Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019.
32536610 2020. Contrasting evidence for corticosteroid treatment for coronavirus-induced cytokine storm.
32616373 2020. The influence of corticosteroid on patients with COVID-19 infection: A meta-analysis.
32616381 2020. A critical evaluation of glucocorticoids in the management of severe COVID-19.
32634602 2020. Corticosteroid therapy for patients with CoVID-19 pneumonia: a before-after study.
32656044 2020. Pulse Therapy With Corticosteroids and Intravenous Immunoglobulin in the Management of Severe Tocilizumab-Resistant COVID-19: A Report of Three Clinical Cases.
32659271 2020. Pros and cons of corticosteroid therapy for COVID-19 patients.
32668178 2020. Inhaled Corticosteroids and COVID-19.
32671349 2020. Evidence of Steroids in Patients With Acute Respiratory Distress Syndrome in Coronavirus Disease 2019.
32675436 2020. Tailoring steroids in the treatment of COVID-19 pneumonia assisted by CT scans: Three case reports.
32696006 2020. Corticosteroid Administration Is Associated With Improved Outcome in Patients With Severe Acute Respiratory Syndrome Coronavirus 2-Related Acute Respiratory Distress Syndrome.
32697000 2020. Corticosteroids-induced osteonecrosis in COVID-19: a call for caution.
32719766 2020. Clinical Use of Short-Course and Low-Dose Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia Progression.
32720612 2020. [Steroid pulse therapy (WAYFARER Study)].
32668164 2020. Reply to: Inhaled Corticosteroids and COVID-19.
32726951 2020. Efficacy of Corticosteroids in Patients with SARS, MERS and COVID-19: A Systematic Review and Meta-Analysis.
32730151 2020. Time-critical administration of corticosteroid rescue therapy for COVID-19 pneumonitis in a ward-based patient with chronic obstructive pulmonary disease.
32734777 2020. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis.
32738928 2020. Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?
32744591 2020. The Uncertain Role of Corticosteroids in the Treatment of COVID-19.
32744600 2020. The Uncertain Role of Corticosteroids in the Treatment of COVID-19-Reply.
32744622 2020. The Uncertain Role of Corticosteroids in the Treatment of COVID-19.
32756215 2020. Therapeutic response to corticosteroids in a critically ill patient with COVID-19: A case report.
32761166 2020. COVID-19 and Dexamethasone: A Potential Strategy to Avoid Steroid-Related Strongyloides Hyperinfection.
32760915 2020. Glucocorticoids save lives in COVID-19 patients.
32763262 2020. The proper use of corticosteroids for 2019-nCov pneumonia: Towards promising results?
32767349 2020. Corticosteroid therapy for patients with severe novel Coronavirus disease 2019.
32769659 2020. Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19).
32778507 2020. COVID-19 and steroid therapy: Impact on diabetes.
32778829 2020. After 62 years of regulating immunity, dexamethasone meets COVID-19.
32792492 2020. Clinical characteristics and corticosteroids application of different clinical types in patients with corona virus disease 2019.
32795143 2020. Corticosteroid prevents COVID-19 progression within its therapeutic window: a multicentre, proof-of-concept, observational study.
32796809 2020. Short-Term Corticosteroid Therapy for Early Exacerbation of COVID-19 Pneumonia: A Case Report.
32802540 2020. Oral Corticosteroid Relieves Post-COVID-19 Anosmia in a 35-Year-Old Patient.
32819962 2020. Steroids in COVID-19: An overview. |
32829047 2020. CORTICOSTEROIDS IN THE TREATMENT OF SEVERE COVID-19 LUNG DISEASE.
32860209 2020. What we have to know about corticosteroids use during Sars-Cov-2 infection.
32860964 2020. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19).
32861345 2020. Migratory Pulmonary Infiltrates in a Patient With COVID-19 Infection and the Role of Corticosteroids.
32868989 2020. Combination treatment of short-course systemic corticosteroid and favipiravir in a successfully treated case of critically ill COVID-19 pneumonia with COPD.
32876693 2020. Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic.
32876689 2020. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
32876695 2020. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.
32876694 2020. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.
32876697 2020. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
32878286 2020. Duration of COVID-19: Data from an Italian Cohort and Potential Role for Steroids.
32880102 2020. Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study.
32880390 2020. Systemic corticosteroids and mortality in severe and critical COVID-19 patients in Wuhan, China.
32881007 2020. Are the steroids a blanket solution for COVID-19? a systematic review and meta-analysis.
32888976 2020. Early short-course corticosteroids and furosemide combination to treat non-critically ill COVID-19 patients: An observational cohort study.
32900168 2020. Pasient med alvorlig covid-19 behandlet med steroider.
32903258 2020. Efficacy of corticosteroids in non-intensive care unit patients with COVID-19 pneumonia from the New York Metropolitan region.
32903363 2020. Corticosteroid Use in the Treatment of COVID-19: A Multicenter Retrospective Study in Hunan, China.
32931775 2020. The association between corticosteroid uses and mortality among severe COVID-19 patients.
32936438 2020. Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All.
32941927 2020. Corticosteroid therapy is associated with the delay of SARS-CoV-2 clearance in COVID-19 patients.
32948881 2020. Corticosteroid-related in-hospital hyperglycemia: does it negate mortality benefits in COVID-19?
32953385 2020. Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All.
32971254 2020. Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study.
32976118 2020. Corticosteroids, COVID-19 pneumonia, and acute respiratory distress syndrome.
32983928 2020. The Application of Corticosteroids in COVID-19: A Two-edged Sword.
32986226 2020. Effect of Corticosteroid Therapy on the Duration of SARS-CoV-2 Clearance in Patients with Mild COVID-19: A Retrospective Cohort Study.
32988730 2020. Corticosteroids as adjunctive therapy in the treatment of coronavirus disease 2019: A report of two cases and literature review.
33005428 2020. Late i.v. steroid treatment for severe COVID-19-induced acute respiratory distress syndrome: a case report.
33007478 2020. Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19.
33008778 2020. Association of corticosteroids use and outcomes in COVID-19 patients: A systematic review and meta-analysis.
33013412 2020. Efficacy and Safety of Corticosteroid Treatment in Patients With COVID-19: A Systematic Review and Meta-Analysis. |
33026460 2020. The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19. |
33043249 2020. Reactivation of SARS-CoV-2 after Asymptomatic Infection while on High-Dose Corticosteroids. Case Report.
33055254 2020. The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells. |
33062586 2020. Corticosteroids: A Controversial Therapy for Coronavirus Disease 2019.
33068560 2020. Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon. |
33083317 2020. Corticosteroids on the Management of Coronavirus Disease 2019 (COVID-19): A Systemic Review and Meta-Analysis. |
33083917 2020. High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study.
33094701 2020. Potential therapeutic use of corticosteroids as SARS CoV-2 main protease inhibitors: a computational study.
33100248 2020. Effectiveness of steroid treatment for SARS-CoV-2 pneumonia with COP-like reaction: a case report.
33103063 2020. Corticosteroids in COVID-19: Is it Rational? A Systematic Review and Meta-Analysis.
33107607 2020. Corticosteroids for COVID-19 patients requiring oxygen support? Yes, but not for everyone: Effect of corticosteroids on mortality and intensive care unit admission in patients with COVID-19 according to patients' oxygen requirements.
33115658 2020. Lack of detrimental effect of corticosteroids on antibody responses to SARS-CoV-2 and viral clearance in patients hospitalized with COVID-19.
33115684 2020. COVID-19, steroids and other immunomodulators: The jigsaw is not complete.
33119227 2020. Use of corticosteroids in SARS-CoV-2 infection: foe, or can they become a friend?
33121512 2020. Corticosteroids in severe COVID-19: a critical view of the evidence.
33123934 2020. Delayed hospital admission and high-dose corticosteroids potentially prolong SARS-CoV-2 RNA detection duration of patients with COVID-19.
33129791 2020. "Impact of Corticosteroids in COVID-19 Outcomes: Systematic Review and Meta-Analysis".
33141117 2020. Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome.
33156381 2020. Impact of late administration of corticosteroids in COVID-19 ARDS.
33172477 2020. Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis.
33173161 2020. Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia.
33180190 2020. Steroid administration in the Covid-19 era; timing does matter!
33183091 2020. Time-course analysis reveals that corticosteroids resuscitate diminished CD8+ T cells in COVID-19: a retrospective cohort study. |
33183113 2020. Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: a benefit of inhaled corticosteroids?
33194871 2020. Late Worsening of COVID-19 Pneumonia: Successful Treatment with Ruxolitinib and Steroid.
33219091 2020. Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management.
33221521 2020. Corticosteroid therapy in COVID-19 patients: Don't forget venous thromboembolism. |
33229355 2020. Efficacite et innocuite des corticosteroides dans le traitement de la COVID-19 selon des donnees pour la COVID-19, d'autres infections aux coronavirus, l'influenza, la pneumonie extrahospitaliere et le syndrome de detresse respiratoire aigue : revue systematique et meta-analyse.
33235253 2020. Low-dose corticosteroid combined with immunoglobulin reverses deterioration in severe cases with COVID-19.
33235888 2020. Antivirals With Adjunctive Corticosteroids Prevent Clinical Progression of Early Coronavirus 2019 Pneumonia: A Retrospective Cohort Study.
33245242 2020. Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-2019.
33248469 2020. Corticosteroids for COVID-19: the search for an optimum duration of therapy.
33249430 2020. Effect of steroids on Covid-19 mortality risk: a Bayesian interpretation.
33249945 2020. Corticosteroids treatment in severe patients with COVID-19: a propensity score matching study.
33254551 2020. Can roflumilast become steroid-sparing alternative in the treatment of COVID-19?
33260010 2020. COVID-19 and non-COVID ARDS patients demonstrate a distinct response to low dose steroids- A retrospective observational study.
33262415 2020. A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19. |
33263084 2020. Association between high-dose steroid therapy, respiratory function, and time to discharge in patients with COVID-19: Cohort study.
33264251 2020. Use of Corticosteroids in COVID-19: Should It Be Considered as a Standard-of-Care Therapy?
33274479 2020. Cyclosporine A plus low-dose steroid treatment in COVID-19 improves clinical outcomes in patients with moderate to severe disease. A pilot study.
33277573 2020. Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19.
33280066 2020. Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study.
33282314 2021. Improvement of COVID-19 with renal failure and paralytic ileus by using steroids.
33290446 2020. Efficacy of corticosteroid therapy in the treatment of long- lasting olfactory disorders in COVID-19 patients.
33298370 2020. Corticosteroids for Patients With Coronavirus Disease 2019 (COVID-19) With Different Disease Severity: A Meta-Analysis of Randomized Clinical Trials.
33301928 2020. Corticosteroids in patients hospitalised for COVID-19 pneumonia who require oxygen: observational comparative study using routine care data.
C7255263 2020. Use of corticosteroids in asthma and COPD patients with or without COVID-19.
C7298510 ?. Steroids: A Therapeutic Option for COVID-19 Pneumonia Patients With ESRD?
C7303657 ?. Systemic steroids and risk of fecal-oral shedding and increased transmission of SARS-Cov-2 in pemphigus cases???.
C7346767 2020. The use of corticosteroids for COVID-19 infection.
C7598544 2020. 153 Do Hydroxychloroquine Disease-Modifying Antirheumatic Agents or Steroids Serve to Prevent COVID-19 Infection?
C7661810 2020. Tocilizumab/unspecified corticosteroids: Spinal epidural abscess: 2 case report.
C7677437 2020. Enoxaparin sodium/methylprednisolone: Cytomegalovirus reactivation gastrointestinal haemorrhage and off-label use: case report.
C7726300 2020. Methylprednisolone/tocilizumab: Disseminated strongyloidiasis and off-label use: case report.
C7726305 2020. Gasorelin/prednisolone: COVID-19 infection and weight increase : case report.
32696008 2020. The Combination of Tocilizumab and Methylprednisolone Along With Initial Lung Recruitment Strategy in Coronavirus Disease 2019 Patients Requiring Mechanical Ventilation: A Series of 21 Consecutive Cases.
32772069 2020. Clinical Outcomes Associated with Methylprednisolone in Mechanically Ventilated Patients with COVID-19.
32785710 2020. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial.
32816700 2020. Response to: 'High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumab' by Conticini et al.
32816701 2020. High dosage of methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to tocilizumab.
32845289 2020. Methylprednisolone for COVID-19: Was Benjamin Rush prescient?
32893160 2020. Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases.
32943404 2020. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial.
32954492 2020. The role of methylprednisolone on preventing disease progression for hospitalized patients with severe COVID-19.
32960899 2020. Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data.
32995261 2020. Methylprednisolone pulse therapy: An alternative management of severe COVID-19.
33072814 2020. Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia.
33109497 2020. Computational studies reveal mechanism by which quinone derivatives can inhibit SARS-CoV-2. Study of embelin and two therapeutic compounds of interest, methyl prednisolone and dexamethasone.
33176176 2020. Early, low-dose, short-term methylprednisolone decreased the mortality in critical COVID-19 patients: A multicenter retrospective cohort study.
33194485 2020. Comparison of Efficacy of Dexamethasone and Methylprednisolone in Improving PaO2/FiO2 Ratio Among COVID-19 Patients.
33200031 2020. Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease.
33219551 2020. High-dose methylprednisolone in nonintubated patients with severe COVID-19 pneumonia.
33220354 2020. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study.
33225306 2020. Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease 2019.
33225870 2020. In silico screening predicts common cold drug Dextromethorphan along with Prednisolone and Dexamethasone can be effective against novel Coronavirus disease (COVID-19).
33230502 2020. Successful recovery from coronavirus disease 2019 in a living kidney transplant recipient using low-dose methylprednisolone.
33318924 2020. Successful treatment with methyl-prednisolone pulses for the late phase of COVID-19 with respiratory failure: A single-center case series.
C7212250 2020. Prednisone: Coronavirus disease 2019: case report.
C7303433 2020. Methylprednisolone: Decrease in T cell count following off label use: case report.
C7317072 2020. Methylprednisolone/prednisone: Accelerated viral replication following an off-label treatment: case report.
C7648232 2020. Prednisolone/tacrolimus: COVID-19 infection: case report.
33229384 2020. Dexamethasone or hydrocortisone in COVID-19?
33232277 2020. Estimating the release of inflammatory factors and use of glucocorticoid therapy for COVID-19 patients with comorbidities.
33308854 ?. Cuestiones por resolver en el tratamiento con glucocorticoides de la infección COVID-19.
C7351423 ?. Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection?.
C7648207 2020. Adalimumab/anakinra/dexamethasone: COVID-19 infection cytomegalovirus reactivation and off-label use: case report.
32620554 2020. Dexamethasone in the management of covid -19.
32636478 2020. Dexamethasone to the rescue.
32674177 2020. Therapie mit Dexamethason bei Patienten mit COVID-19.
32678530 2020. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report.
32684095 2020. Worrying situation regarding the use of dexamethasone for COVID-19.
32690491 2020. Dexamethasone for COVID-19: preliminary findings.
32706553 2020. Audio Interview: Dexamethasone and Covid-19.
32740972 2020. Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes.
32747742 2020. Dexamethasone nanomedicines for COVID-19.
32791213 2020. Dexamethasone: A boon for critically ill COVID-19 patients?
32874905 2020. Dexamethasone in severe COVID-19 infection: A case series.
32887677 2020. Covid-19: Hydrocortisone can be used as alternative to dexamethasone, review finds.
32896649 2020. Dexamethasone to combat cytokine storm in COVID-19: Clinical trials and preliminary evidence.
32922210 2020. Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost?
32922517 2020. Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes.
32924825 2020. Computational insight of dexamethasone against potential targets of SARS-CoV-2. |
33000510 2020. Molecular and functional resemblance of dexamethasone and quercetin: A paradigm worth exploring in dexamethasone-nonresponsive COVID-19 patients.
33023445 2020. Epidemiological Situation and Efficacy of Dexamethasone for the treatment planning of COVID-19: A perspective review.
33035967 2020. COVID-19, myocardial edema and dexamethasone.
33053024 2020. Sindrome do desconforto respiratorio agudo associada a COVID-19 tratada com Dexametasona (CoDEX).
33063792 2020. Molecular determinants of vascular transport of dexamethasone in COVID-19 therapy.
33077267 2020. Chez les sujets hospitalises pour COVID-19, est-ce que la dexamethasone diminue la mortalite a 28jours comparativement au traitement standard ?
33129421 2020. Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties.
33137605 2020. Can dexamethasone prevent the seizures induced by SARS-CoV-2 infection?
33163859 2020. Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review.
33233748 2020. Biomimetic Nanoparticles Potentiate the Anti-Inflammatory Properties of Dexamethasone and Reduce the Cytokine Storm Syndrome: An Additional Weapon against COVID-19?
33251412 2020. Chemocentric Informatics Analysis: Dexamethasone Versus Combination Therapy for COVID-19.
33293892 2020. Dexamethason.
C7343652 2020. The use of dexamethasone in the treatment of COVID-19.